Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07139743 · ClinicalTrials.gov registry record · Phase 1
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
A Phase 1 study of Progressive Multiple Sclerosis, sponsored by Autolus Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT07139743: Recruiting Phase 1 study of Progressive Multiple Sclerosis, sponsored by Autolus Limited.
NCT07139743 is a Phase 1 study of Progressive Multiple Sclerosis that is actively recruiting participants, run by Autolus Limited. The registered enrollment target is 18 participants, below the 21-participant average among 3 other Progressive Multiple Sclerosis trials with a reported enrollment target (14% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07139743, a Phase 1 study of Progressive Multiple Sclerosis, is actively recruiting participants, sponsored by Autolus Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.
Conditions Studied
Interventions
- BIOLOGICAL Obecabtagene autoleucel (obe-cel)
Study Locations (7)
Other
- Hospital Universitario Vall d'Hebron - PPDS - Barcelona
- Hospital Universitari i Politecnic La Fe de Valencia - Valencia
- Addenbrooke's Hospital - Cambridge
- Western General Hospital Edinburgh - PPDSE Edinburgh - Edinburgh
- The National Hospital for Neurology & Neurosurgery - London
- Royal Hallamshire Hospital - Sheffield
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2029-08-15 |
| Phase | Phase 1 |
What NCT07139743 shows while recruiting
NCT07139743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 21-participant average among 3 other Progressive Multiple Sclerosis trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Obecabtagene autoleucel (obe-cel) is the first listed.
NCT07139743 lists 7 locations in 2 states (Other, California).
Frequently Asked Questions
What is clinical trial NCT07139743 about?
NCT07139743 is a clinical study titled "Obe-cel in Refractory Progressive Forms of Multiple Sclerosis". The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population c...
What is the current status of trial NCT07139743?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-08-04. Estimated completion is 2029-08-15.
What conditions does trial NCT07139743 study?
This clinical trial studies the following conditions: Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT07139743?
The interventions under investigation include: Obecabtagene autoleucel (obe-cel) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07139743?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07139743 being conducted?
This trial has 7 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ABA-101 in Participants With Progressive Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI